Replies to post #133812 on Biotech Values

[DewDiligence]

I might accept this as an explanation for the 9 pct - but it isn't the part of the deal I find low - because it isn't the part of the deal that focuses on MNTA's special sauce and I wouldn't expect much recompense in such a competitive space.

Your attempt to compartmentalize the economic terms of the deal is without merit, IMO.

The risk that interchangeable FoB’s won’t pass muster with regulators—which is disproportionally being borne by BAX—surely affected the economic terms of the partnership in the aggregate insofar as the partnership terms resulted from a negotiation in which the various provisions were traded off against one another.